Literature DB >> 387372

Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states.

R N Brogden, R C Heel, T M Speight, G S Avery.   

Abstract

Naproxen is a propionic acid derivative with analgesic and anti-inflammatory activity which has been widely used in the treatment of rheumatic diseases. Naproxen has been well studied in rheumatoid arthritis and is as effective as aspirin but better tolerated, thus enabling more patients to continue with treatment. For this reason some clinicians now prefer to try propionic acid derivatives, such as naproxen, before aspirin in arthritic patients. In comparative studies with other non-steroidal anti-inflammatory drugs, such as indomethacin, ibuprofen, fenoprofen and others, all drugs were usually of similar overall efficacy although naproxen was sometimes preferred: but as with other non-steroidal anti-inflammatory agents, not all patients will respond to naproxen and in such cases other agents should also be tried until the most satisfactory drug is found for each patient. Naproxen is also effective in degenerative joint diseases of the hip and knee, although further well designed studies are needed to more clearly define its relative place compared with newer drugs such as diclofenac or diflunisal. Results of other comparative studies have shown that naproxen is a suitable alternative to phenylbutazone or indomethacin in ankylosing spondylitis and to aspirin in juvenile rheumatoid arthritis. Naproxen appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with pain following surgery or trauma and in pain of dysmenorrhoea. Naproxen has generally been better tolerated than aspirin or indomethacin at the dosages used. Because of its relatively long plasma half-life, naproxen can with convenieice be given twice daily, and there is some evidence that once daily dosage is as effective in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 387372     DOI: 10.2165/00003495-197918040-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  161 in total

1.  Scintiscan evaluation of rheumatoid hands for monitoring the anti-inflammatory effects of drugs.

Authors:  J Remans; H Berghs; L Drieskens; L Kiebooms; J Polderman
Journal:  J Belge Rhumatol Med Phys       Date:  1976 Jul-Aug

2.  [Naproxen: Corticosteroid sparing effect in rheumatoid arthritis].

Authors:  J B Flores
Journal:  Scand J Rheumatol Suppl       Date:  1973

3.  Gastro-intestinal bleeding under treatment with naproxen.

Authors:  G Curtarelli; M Romussi
Journal:  Scand J Rheumatol Suppl       Date:  1973

4.  The delay of spontaneous labor by Naproxen in the rat model.

Authors:  A I Csapo; E F Csapo; E Fay; M R Henzl; G Salau
Journal:  Prostaglandins       Date:  1973-06

5.  Gastric effects of propoxyphene, acetaminophen, indomethacin, phenylbutazone, and naproxen.

Authors:  N S Mann; A J Sachdev
Journal:  J Ky Med Assoc       Date:  1977-01

6.  Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects.

Authors:  R Runkel; M Chaplin; G Boost; E Segre; E Forchielli
Journal:  J Pharm Sci       Date:  1972-05       Impact factor: 3.534

7.  The comparative gastric ulcerogenic activities of non-steroid anti-inflammatory drugs.

Authors:  K D Rainsford
Journal:  Agents Actions       Date:  1977-12

8.  A long-term comparison of proquazone and naproxen in the treatment of osteoarthritis of the hip.

Authors:  J T Vainio; P V Lepistö
Journal:  Scand J Rheumatol Suppl       Date:  1978

9.  Kinetics of analgesic response in man; an example with two non-steroidal anti-inflammatory analgesic drugs.

Authors:  G Sacchetti; G C Ferrati; L Parrinello; A Salami
Journal:  J Int Med Res       Date:  1978       Impact factor: 1.671

10.  Asprin and codeine in two postpartum pain models.

Authors:  S S Bloomfield; T P Barden; J Mitchell
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

View more
  26 in total

1.  Prostaglandin E2 does not regulate total or myofibrillar protein breakdown in incubated skeletal muscle from normal or septic rats.

Authors:  P O Hasselgren; O Zamir; J H James; J E Fischer
Journal:  Biochem J       Date:  1990-08-15       Impact factor: 3.857

2.  The effect of anti-inflammatory and anti-rheumatic drugs on cell accumulation onto nitrocellulose discs implanted subcutaneously into mice.

Authors:  A P Green; F R Mangan
Journal:  Agents Actions       Date:  1983-06

3.  Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics.

Authors:  B Whiting; R L Williams; M Lorenzi; J C Varady; D S Robins
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

4.  Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent.

Authors:  P J Pentikäinen; P J Neuvonen; C Backman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 5.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

6.  Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction.

Authors:  Raymond G Schlienger; Hershel Jick; Christoph R Meier
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 7.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

Review 8.  Non-steroidal anti-inflammatory analgesics other than salicylates.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

9.  Prostaglandin synthesis and fatty acid composition of phospholipids and triglycerides in skeletal muscle of chicks fed combinations of flaxseed oil and animal tallow.

Authors:  J M Olomu; V E Baracos
Journal:  Lipids       Date:  1991-09       Impact factor: 1.880

10.  Piroxicam in human breast milk.

Authors:  M Ostensen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.